Resource impact summary report
NICE has produced a resource impact summary report that incorporates the following technology appraisal guidance for treating hormone‑sensitive metastatic prostate cancer:
- Apalutamide with androgen deprivation therapy for treating hormone-sensitive metastatic prostate cancer (2021) NICE technology appraisal guidance 741
- Enzalutamide for treating hormone-sensitive metastatic prostate cancer (2021) NICE technology appraisal guidance 712
This page was last updated: